「Meningococcus」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
56行目: | 56行目: | ||
**Menveo (GSK) | **Menveo (GSK) | ||
**Nimenrix (Pfizer) | **Nimenrix (Pfizer) | ||
− | *B polysaccharide | + | *B protein (not polysaccharide) |
**Bexsero (GSK) | **Bexsero (GSK) | ||
**Trumenba (Pfizer) | **Trumenba (Pfizer) |
2021年6月1日 (火) 12:11時点における版
Navigation Menu | ![]() |
展開するGeneral issues of Vaccine |
---|
展開するGeneral issues of Tropical med. |
---|
展開するGeneral issues of Travel med. |
---|
展開するImmunology |
---|
展開するEpi & Stats |
---|
展開するVirus |
---|
展開するCOVID-19 |
---|
展開するBacteria |
---|
展開するRickettsia |
---|
展開するProtozoa |
---|
展開するFungi |
---|
展開するNematode (roundworm) |
---|
展開するTrematode (fluke, distoma) |
---|
展開するCestode (tapeworm) |
---|
展開するMedical Zoology |
---|
目次
pathogen
- Neisseria meningitidis
- gram negative diplococci
- carriage in nasopharynx
- 12 identified capsular serogroups
- common pathogenic serogroup A, B, C, W, X, Y
- seasonal epidemics by group A, C
- meningitis belt
- sporadic cases by e.g. group B
- Latin America
- Norway
- New Zealand
- immunity generated by polysaccharide capsule except B
- may be the reason that herd immunity development relatively slow and sporadic outbreaks continue in above countries
epidemiology
- highest < 2 y/o and adolescent
- annual outbreak during dry season in meningitis belt
- dry winds make people's nose drier resulting in easy
- wide range difference of nasopharynx carriage between countries
- reason totally unknown
- NZ & 3%
- Nigeria boarding house 30-40%
transmission
- aerosol
- fomite
- adolescent activity
clinical picture
- fever
- distinctive petechiae anywhere in whole body
- no fading by pressure with glass tumbler - "tumbler test"
- resulting in purple bruising of skin
- photophobia
- headache, neck stiffness, vomiting
- irritability and/or confusion
vaccine
development history
- 1960s - purified PS vaccines for A and C
- immunity short term due to lack of T-cell involvement
- 1990s - conjugated vaccines for A and C after success of Hib conjugate vaccine
- 2000s - monovalent A vaccine for Africa
- "MenAfriVac"
current vaccines
- A polysaccharide
- MenAfriVac
- C conjugate
- A,C,Y,W135 conjugate
- Menactra (Sanofi Pasteur)
- Menveo (GSK)
- Nimenrix (Pfizer)
- B protein (not polysaccharide)
- Bexsero (GSK)
- Trumenba (Pfizer)
- VA-MENGOC-BC (Finlay Institute of Cuba)
issues of men B vaccine
- polysaccharide of B is relatively low immunogenic
- the reason is considered because of interaction between B polysaccharide and fetal brain tissue, resulting in possible immunotolerance
- interaction is observed as antibodies against B-PS have also affinity to fetal brain tissue
- it means B-PS vaccine has potential of neurological damage for young infants
- the reason is considered because of interaction between B polysaccharide and fetal brain tissue, resulting in possible immunotolerance
- currently available men B vaccines are protein-based vaccine, not PS vaccine
- proteins expressed on the surface of N. meningitidis group B are purified through bacterial culture